OncoMatch

OncoMatch/Clinical Trials/NCT05629494

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Is NCT05629494 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Ibuprofen 400 mg, TID for prostate cancer.

Phase 4RecruitingAlbany Medical CollegeNCT05629494Data as of May 2026

Treatment: Ibuprofen 400 mg, TIDProstate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Prior therapy

Cannot have received: 5-alpha reductase inhibitor (finasteride, dutasteride)

Exception: unless patient has been taking it for at least 6 months

Concomitant use of 5-alpha reductase inhibitors (finasteride, dutasteride) unless patient has been taking it for at least 6 months

Cannot have received: anti-inflammatory or steroidal drugs

Concomitant anti-inflammatory or steroidal drugs

Cannot have received: dual-antiplatelet or anticoagulant therapy

Exception: except aspirin 81 mg alone

Concomitant dual-antiplatelet or anticoagulant therapy use except aspirin 81 mg alone

Lab requirements

Kidney function

No severe chronic kidney disease: eGFR < 30 mL/min/1.73 m2

Liver function

No severe liver disease (abnormal liver function tests: AST or ALT > 3X ULN)

Cardiac function

No heart failure, significant heart disease, or poorly controlled hypertension

Known severe chronic kidney disease: eGFR < 30 mL/min/1.73 m2; Know history of severe liver disease determined by abnormal liver function tests (elevated AST or ALT > 3X ULN based on exiting history or labs); Heart failure, significant heart disease; Poorly controlled hypertension

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Chicago Medical Center · Chicago, Illinois
  • Albany Medical Center · Albany, New York
  • Penn State-Hershey Medical Center · Hershey, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify